These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 8734302)

  • 21. Dopaminergic neurons reduced to silence by oxidative stress: an early step in the death cascade in Parkinson's disease?
    Michel PP; Ruberg M; Hirsch E
    Sci STKE; 2006 Apr; 2006(332):pe19. PubMed ID: 16639033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity.
    Varadarajan S; Yatin S; Aksenova M; Butterfield DA
    J Struct Biol; 2000 Jun; 130(2-3):184-208. PubMed ID: 10940225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease?
    Andersen JK
    Novartis Found Symp; 2001; 235():11-20; discussion 20-5. PubMed ID: 11280021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxidative stress, age-related neurodegeneration, and the potential for neurotrophic treatment.
    Williams LR
    Cerebrovasc Brain Metab Rev; 1995; 7(1):55-73. PubMed ID: 7742172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melatonin oxidative stress and neurodegenerative diseases.
    Srinivasan V
    Indian J Exp Biol; 2002 Jun; 40(6):668-79. PubMed ID: 12587715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel imine antioxidants at low nanomolar concentrations protect dopaminergic cells from oxidative neurotoxicity.
    Hajieva P; Mocko JB; Moosmann B; Behl C
    J Neurochem; 2009 Jul; 110(1):118-32. PubMed ID: 19486265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment.
    Frölich L; Riederer P
    Arzneimittelforschung; 1995 Mar; 45(3A):443-6. PubMed ID: 7763342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo induction of heat shock proteins in the substantia nigra following L-DOPA administration is associated with increased activity of mitochondrial complex I and nitrosative stress in rats: regulation by glutathione redox state.
    Calabrese V; Mancuso C; Ravagna A; Perluigi M; Cini C; De Marco C; Butterfield DA; Stella AM
    J Neurochem; 2007 May; 101(3):709-17. PubMed ID: 17241115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxidative damage and Alzheimer's disease: are antioxidant therapies useful?
    Moreira PI; Smith MA; Zhu X; Honda K; Lee HG; Aliev G; Perry G
    Drug News Perspect; 2005; 18(1):13-9. PubMed ID: 15753972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxidative stress and the pathogenesis of neurodegenerative disorders.
    Reynolds A; Laurie C; Mosley RL; Gendelman HE
    Int Rev Neurobiol; 2007; 82():297-325. PubMed ID: 17678968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Environmental-induced oxidative stress in neurodegenerative disorders and aging.
    Migliore L; Coppedè F
    Mutat Res; 2009 Mar; 674(1-2):73-84. PubMed ID: 18952194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aging, energy, and oxidative stress in neurodegenerative diseases.
    Beal MF
    Ann Neurol; 1995 Sep; 38(3):357-66. PubMed ID: 7668820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group.
    Jenner P; Dexter DT; Sian J; Schapira AH; Marsden CD
    Ann Neurol; 1992; 32 Suppl():S82-7. PubMed ID: 1510385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PPAR: a therapeutic target in Parkinson's disease.
    Chaturvedi RK; Beal MF
    J Neurochem; 2008 Jul; 106(2):506-18. PubMed ID: 18384649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease.
    Ahlskog JE; Uitti RJ; Low PA; Tyce GM; Nickander KK; Petersen RC; Kokmen E
    Mov Disord; 1995 Sep; 10(5):566-73. PubMed ID: 8552107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurotransmitters and neurodegenerative disorders.
    Kanazawa I
    Clin Ther; 1984; 7 Spec No():48-58. PubMed ID: 6152198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mechanism of cell death in neurodegenerative disorders: apropos of Parkinson disease].
    Agid Y
    C R Seances Soc Biol Fil; 1993; 187(1):37-46. PubMed ID: 8242421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxidation reactions in Parkinson's disease.
    Olanow CW
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 32-7; discussion 37-9. PubMed ID: 2215972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease.
    Jenner P
    Acta Neurol Scand Suppl; 1993; 146():6-13. PubMed ID: 8333254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxidative stress and Parkinson's disease.
    Owen AD; Schapira AH; Jenner P; Marsden CD
    Ann N Y Acad Sci; 1996 Jun; 786():217-23. PubMed ID: 8687021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.